Adverse events following measles, mumps, rubella and varicella virus vaccine live (PROQUAD^®) reported to the vaccine adverse event reporting system (VAERS), 2015-2025.

ABSTRACT:

Background

PROQUAD^®, a quadrivalent live-attenuated vaccine targeting measles, mumps, rubella, and varicella, is widely used in pediatric immunization programs. While clinical trials and post-marketing studies have established its general safety, real-world evidence from large-scale passive surveillance systems remains limited.

Methods

We performed a disproportionality analysis of PROQUAD-related adverse events (AEs) reported to the Vaccine Adverse Event Reporting System (VAERS) between 2015 and 2025. Multiple statistical algorithms were applied to detect safety signals, supplemented by stratified analyses across age, sex, severity, and fatal outcomes.

Results

Among 17,234 reports, the most frequently reported AEs included injection site erythema, swelling,

SUBMITTER: Liang G 

PROVIDER: S-EPMC12750890 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature